102 related articles for article (PubMed ID: 12426520)
1. Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.
Lee CR; Pieper JA; Hinderliter AL; Blaisdell JA; Goldstein JA
Clin Pharmacol Ther; 2002 Nov; 72(5):562-71. PubMed ID: 12426520
[TBL] [Abstract][Full Text] [Related]
2. [Influence of cytochrom P450 CYP2C9 polymorphism on the pharmacokinetics of tolbutamide metabolism using oligonucleotide genotyping microarray].
Li J; Wen SY; Wang R; Chen K; Fang Y; Pei F; Wang SQ
Yao Xue Xue Bao; 2005 Aug; 40(8):695-9. PubMed ID: 16268502
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam.
Perini JA; Vianna-Jorge R; Brogliato AR; Suarez-Kurtz G
Clin Pharmacol Ther; 2005 Oct; 78(4):362-9. PubMed ID: 16198655
[TBL] [Abstract][Full Text] [Related]
4. Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers.
Ma JD; Nafziger AN; Kashuba AD; Kim MJ; Gaedigk A; Rowland E; Kim JS; Bertino JS
J Clin Pharmacol; 2004 Jun; 44(6):570-6. PubMed ID: 15145963
[TBL] [Abstract][Full Text] [Related]
5. Relationship of P450 2C9 genetic polymorphisms in Chinese and the pharmacokinetics of tolbutamide.
Chen K; Wang R; Wen SY; Li J; Wang SQ
J Clin Pharm Ther; 2005 Jun; 30(3):241-9. PubMed ID: 15896241
[TBL] [Abstract][Full Text] [Related]
6. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans.
Lee CR; Pieper JA; Frye RF; Hinderliter AL; Blaisdell JA; Goldstein JA
J Clin Pharmacol; 2003 Jan; 43(1):84-91. PubMed ID: 12520632
[TBL] [Abstract][Full Text] [Related]
7. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.
Thijssen HH; Ritzen B
Clin Pharmacol Ther; 2003 Jul; 74(1):61-8. PubMed ID: 12844136
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
[TBL] [Abstract][Full Text] [Related]
9. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
10. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
Shon JH; Yoon YR; Kim KA; Lim YC; Lee KJ; Park JY; Cha IJ; Flockhart DA; Shin JG
Pharmacogenetics; 2002 Mar; 12(2):111-9. PubMed ID: 11875365
[TBL] [Abstract][Full Text] [Related]
11. Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects.
Bae JW; Kim JH; Choi CI; Kim MJ; Kim HJ; Byun SA; Chang YS; Jang CG; Park YS; Lee SY
Arch Pharm Res; 2009 Feb; 32(2):269-73. PubMed ID: 19280158
[TBL] [Abstract][Full Text] [Related]
12. Microdose pharmacogenetic study of ¹⁴C-tolbutamide in healthy subjects with accelerator mass spectrometry to examine the effects of CYP2C9∗3 on its pharmacokinetics and metabolism.
Ikeda T; Aoyama S; Tozuka Z; Nozawa K; Hamabe Y; Matsui T; Kainuma M; Hasegawa S; Maeda K; Sugiyama Y
Eur J Pharm Sci; 2013 Jul; 49(4):642-8. PubMed ID: 23727057
[TBL] [Abstract][Full Text] [Related]
13. Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers.
Vormfelde SV; Brockmöller J; Bauer S; Herchenhein P; Kuon J; Meineke I; Roots I; Kirchheiner J
Clin Pharmacol Ther; 2009 Jul; 86(1):54-61. PubMed ID: 19369937
[TBL] [Abstract][Full Text] [Related]
14. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
Niemi M; Cascorbi I; Timm R; Kroemer HK; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
[TBL] [Abstract][Full Text] [Related]
16. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 2C9 phenotyping using low-dose tolbutamide.
Jetter A; Kinzig-Schippers M; Skott A; Lazar A; Tomalik-Scharte D; Kirchheiner J; Walchner-Bonjean M; Hering U; Jakob V; Rodamer M; Jabrane W; Kasel D; Brockmöller J; Fuhr U; Sörgel F
Eur J Clin Pharmacol; 2004 May; 60(3):165-71. PubMed ID: 15045499
[TBL] [Abstract][Full Text] [Related]
18. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype.
Zhang Y; Zhong D; Si D; Guo Y; Chen X; Zhou H
Br J Clin Pharmacol; 2005 Jan; 59(1):14-7. PubMed ID: 15606435
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the pharmacokinetic interaction between ticagrelor and tolbutamide, a cytochrome P450 2C9 substrate, in healthy volunteers.
Teng R; Mitchell P; Butler K
Int J Clin Pharmacol Ther; 2013 Apr; 51(4):305-12. PubMed ID: 23380426
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P4502C9 genotype in Southeast Anatolia and possible relation with some serum tumour markers and cytokines.
Yilmaz N; Erbağci AB; Aynacioğlu AS
Acta Biochim Pol; 2001; 48(3):775-82. PubMed ID: 11833786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]